title: Long-term clinical outcome of titanium-nitride-oxide-coated stents versus everolimus-eluting stents in acute coronary syndrome: Final report of the BASE ACS trial.
abstract: BACKGROUND
  The BASE ACS randomized trial demonstrated non-inferiority of titanium-nitride-oxide-coated bioactive stents (BAS), compared with everolimus-eluting stents (EES), for the primary endpoint of major adverse cardiac events (MACE) in patients presenting with acute coronary syndrome (ACS) at 12-month follow-up. We report the final long-term clinical outcome of the trial.
  
  
  METHODS
  We randomly assigned 827 patients with ACS to receive either BAS (417) or EES (410). The primary endpoint was MACE: a composite of cardiac death, non-fatal myocardial infarction (MI) or ischemia-driven target lesion revascularization (TLR) at 12-month follow-up. Analysis was performed by intention to treat. Follow-up was planned at 12months, and yearly thereafter through 7years.
  
  
  RESULTS
  Mean follow-up duration was 4.2±1.9years (median 5.0years). At 5-year follow-up, BAS was non-inferior to EES for the primary endpoint of MACE (14.4% versus 17.8%, respectively; hazard ratio for BAS versus EES, 0.82; 95% confidence interval, 0.58-1.16; p=0.26 for superiority; p<0.001 for non-inferiority). The rate of non-fatal MI was lower in the BAS group (5.9% versus 9.7%, respectively, p=0.028). The rates of cardiac death and ischemia-driven TLR were comparable (2.8% versus 3.8%, and 8.3% versus 9.9%; p=0.76 and p=0.58, respectively).
  
  
  CONCLUSIONS
  In the current final report of the randomized BASE ACS trial in patients with ACS, BAS implantation was associated with a rate of cumulative MACE at long-term follow-up that was statistically non-inferior to EES.
authors: Heart Center, Satakunta Central Hospital, Pori, Finland. Electronic address: pasi.karjalainen@satshp.fi.
authors: Pasi P
authors: PP
authors: Karjalainen
authors: Heart Center, Satakunta Central Hospital, Pori, Finland.
authors: Wail
authors: W
authors: Nammas
authors: Heart Center, Satakunta Central Hospital, Pori, Finland.
authors: Antti
authors: A
authors: Ylitalo
authors: Cardiovascular Center Aalst, OLV-Clinic, Aalst, Belgium.
authors: Bernard
authors: B
authors: de Bruyne
authors: CHU de Charleroi, Charleroi, Belgium.
authors: Jacques
authors: J
authors: Lalmand
authors: Department of Cardiology, Brighton and Sussex University Hospital NHS Trust, Brighton, UK.
authors: Adam
authors: A
authors: de Belder
authors: Interventional Cardiology Section, La Princesa University Hospital, Madrid, Spain.
authors: Fernando
authors: F
authors: Rivero-Crespo
authors: Clinical Research Center, Oulu University Hospital, University of Oulu, Oulu, Finland.
authors: Kari
authors: K
authors: Kervinen
authors: Heart Center, Turku University Hospital, Turku, Finland.
authors: Juhani K E
authors: JKE
authors: Airaksinen
mesh_terms: D054058:Acute Coronary Syndrome / Q000401:mortality* / Q000601:surgery*; D000368:Aged; D003643:Death; D054855:Drug-Eluting Stents / Q000639:trends*; D000068338:Everolimus / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000639:trends*; D011446:Prospective Studies; D016037:Single-Blind Method; D013997:Time Factors; D014025:Titanium / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: C434243:titanium-nitride-oxide; D000068338:Everolimus; D014025:Titanium
keywords: Acute coronary syndrome; Everolimus-eluting stents; Outcome; Titanium-nitride-oxide-coated stents